Attralus, Inc is a San Francisco-based biotechnology company that is dedicated to developing innovative therapeutics for systemic amyloidosis. Their groundbreaking pan-amyloid removal (PAR) approach aims to directly bind and eliminate toxic amyloid, offering potential treatment options for all types and stages of this debilitating disease.
With a mission to improve the lives of patients with systemic amyloidosis, Attralus is focused on developing transformational therapeutics that target the underlying disease. Their proprietary technology enables the development of novel biologics and the world's first amyloidosis-specific imaging agent, propelling their strategy to identify and treat all stages and types of patients with this life-threatening condition.
Generated from the website